London South East | The UK's favourite investor portal.

45.2% Mo at 65.3% recovery
6.5g/t Au at 2.3% recovery
128g/t Ag at 0.9% recovery
The metallurgical results have provided excellent results with scope to further improve the copper and lead recoveries through a regrind process to improve the liberation of the chalcocite and galena and expose them to flotation.

The proposed metallurgical flowsheets as developed by Grinding Solutions and Minxcon have been incorporated into the plant refurbishment currently being finalised at the processing plant of Baita Plai. The proposed molybedum recovery circuit will be included in the process flow of the processing plant and will form an additional revenue stream to the Company.

Andrew Prelea, Chief Executive Officer at Vast commented:

“Results from Grinding Solutions test work confirm the Company’s confidence in the quality of the Baita Plai asset and our decision to focus all our attention in bringing Baita Plai in to production.

“The opportunity to further develop the mine and continue exploration at Baita Plai in order to increase the Resource and extend the life of mine is a continuing priority for the Company. These test results underpin both the near term and the future profitability of the Company.”

Vast Resources plc
(“Vast” or the “Company”)

Further Baita Plai Metallurgical Test Work Update

Vast Resources plc, the AIM-listed mining company, is pleased to update the market on progress on metallurgical test work at its Baita Plai Polymetallic Mine “Baita Plai” in Romania.

Test work

Following the previous announcements made on 12 & 15 May & 24 July 2020 regarding the Baita Plai Metallurgical Test Work, the Company can confirm that it has received the final draft report of the results from Grinding Solutions, based in the UK.

Highlights of the test work include:

Copper recoveries range between 88.2% - 93.8% into a copper concentrate
Gold recoveries into the copper concentrate range between 72.7% - 78.2%
Silver recoveries to the copper concentrate range between 69.3% - 83.0%
Zinc recovery of 51.1% into a zinc concentrate with gold and silver credits
Molybedenum recovery of 65.3% into a molybdenum concentrate with gold and silver credits
Gravity recoverable gold potential as visible gold was seen on the shaking tables when attempting the de-leading of copper concentrates
The test work was undertaken on three samples representing high grade copper mineralisation, a polymetallic copper-lead-zinc mineralisation and a copper-molybdenum ore. All three types of mineralisation contain gold and silver mineralisation.

The main copper bearing minerals include bornite, chalcocite and chalcopyrite while the main zinc bearing mineral is sphalerite and the main lead bearing mineral is galena. Liberation of the minerals through milling to 75% passing 80 microns was excellent to good for all minerals except the chalcocite and the galena in samples two and three.

Initial testwork focussed on recreating the historic plant operating parameters. Upon the introduction of pre-conditioning aeration, recoveries dramatically improved in the subsequent test work and optimisation programme.

On the first sample, the higher grade copper sample, the following results were achieved.

Copper Concentrate:

35.2% Cu at 88.2% recovery
14.8g/t Au at 78.2% recovery
954g/t Ag at 76.9% recovery
On the second sample, the polymetallic copper-lead-zinc sample, the following results were achieved.

Copper Concentrate:

43.4% Cu at 93.8% recovery
3.98% Pb at 80.5% recovery
7.48% Zn at 38.9% loss
17.7g/t Au at 75.2% recovery
1393g/t Ag at 83.0% recovery
Zinc Concentrate:

0.70% Cu at 0.2% loss
0.16% Pb at 0.5% loss
62.99% Zn at 51.1% recovery
0.62g/t Au at 0.4% recovery
127g/t Ag at 1.1% recovery
On the third sample, the copper-molybdenum sample, the following results were achieved.

Copper Concentrate:

34.6% Cu at 91.3% recovery
0.15% Mo at 2.9% loss
14.8g/t Au at 72.7% recovery
763g/t Ag at 69.3% recovery
Molybdenum Concentrate:

1.3% Cu at 0.2% loss
45.2% Mo at 65.3% recovery
6.5g/t Au at 2.3% recovery
128g/t Ag at 0.9% recovery
The metallurgical results have provided excellent results with scope to further impr

("Hemogenyx Pharmaceuticals" or the "Company")

Presentations at Cancer Immunotherapy Symposia

Hemogenyx Pharmaceuticals plc (LSE:HEMO) is pleased to announce its participation in this year's Keystone Symposia: Advances in Cancer Immunotherapy, taking place August 17-19, 2020.

The conference highlights challenges in the long-term efficacy of current cancer immunotherapies and provides insights into the mechanistic foundations of and possible solutions to these problems.

Scientists from the Company will present two posters at this year's conference, which will be taking place virtually due to the COVID-19 pandemic. Presentations will be hosted in interactive ePoster sessions, where scientists from Hemogenyx Pharmaceuticals will be available to answer questions about their latest research.

The first poster, entitled "High Affinity FLT3-CD3 Bispecific Antibody Effectively Eliminates AML in Humanized Mouse Models", discusses the company's bispecific CDX antibody, designed for the treatment of acute myeloid leukemia ("AML") and concurrent conditioning of the bone marrow niche for hematopoietic stem cell transplantation ("HSCT").

The second poster, entitled "A Novel Anti-FLT3 CAR-T Therapy for Effective Elimination of AML and Conditioning for Hematopoietic Stem Cell Transplantation", discusses the Company's newest cell therapy, chimeric antigen receptor T cells, which express anti-FLT3 antibodies to target and kill AML and condition HSCT.

The Company's bispecific antibody and CAR-T therapies have shown promising results in both in vitro and in vivo preclinical experiments and display advantages over current standard of care treatments for AML due to their increased specificity and efficacy, underscoring the Company's commitment to breakthrough therapies for the treatment of blood diseases.

Keystone Symposia on Molecular and Cellular Biology (https://goo.gl/epxTuf) is a nonprofit organization with a 48-year history of convening open, peer-reviewed conferences that connect the scientific community and accelerate life science discovery. Its Scientific Advisory Board is comprised of eminent biomedical scientists whose expertise derives from academia, industry, and the government (https://goo.gl/GtwUjT).

Latest Share Chat

Member Info for whitto

Followers

Following

Posts (Last 30 Days)

Posts (All Time)

Last Post

Member Since

Share Chat Post Distribution (Last 30 Days)

Activity Log (Last 30 Days)